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in infants with NS (NS/MPD). We identified PTPN11 mutations in blood or bone marrow specimens
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reports, we compared the spectrum of PTPN11 mutations in 3 groups: (1) patients with JMML (n =
107); (2) patients with NS/MPD (n = 19); and (3) patients with NS (n = 243). Glu76 was the most
commonly affected residue in JMML (n = 45), with the Glu76Lys alteration (n = 29) being most frequent.
Eight of 19 patients with NS/MPD carried the Thr73Ile substitution. These data suggest that there is
a genotype/phenotype correlation in the spectrum of PTPN11 mutations found in patients with JMML,
NS/MPD, and NS. This supports the need to characterize the spectrum of hematologic abnormalities
in individuals with NS and to better define the impact of the PTPN11 lesion on the disease course in
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NEOPLASIA
Brief report
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia
and Noonan syndrome/myeloproliferative disease
Christian P. Kratz, Charlotte M. Niemeyer, Robert P. Castleberry, Mualla Cetin, Eva Bergstra¨sser, Peter D. Emanuel, Henrik Hasle,
Gabriela Kardos, Cornelia Klein, Seiji Kojima, Jan Stary, Monika Trebo, Marco Zecca, Bruce D. Gelb, Marco Tartaglia, and Mignon L. Loh
Germ line PTPN11 mutations cause 50% of
cases of Noonan syndrome (NS). Somatic
mutations in PTPN11 occur in 35% of pa-
tients with de novo, nonsyndromic juvenile
myelomonocytic leukemia(JMML).Myelopro-
liferative disorders (MPDs), either transient
or more fulminant forms, can also occur in
infants with NS (NS/MPD). We identified
PTPN11 mutations in blood or bone marrow
specimens from 77 newly reported patients
with JMML (n 69) or NS/MPD (n 8). To-
gether with previous reports, we compared
the spectrum of PTPN11 mutations in 3
groups: (1) patients with JMML (n 107); (2)
patients with NS/MPD (n 19); and (3) pa-
tients with NS (n 243). Glu76 was the most
commonlyaffectedresidue inJMML(n 45),
with the Glu76Lys alteration (n 29) being
most frequent. Eight of 19 patients with NS/
MPD carried the Thr73Ile substitution. These
data suggest that there is a genotype/pheno-
type correlation in the spectrum of PTPN11
mutations found in patients with JMML, NS/
MPD, and NS. This supports the need to
characterize the spectrum of hematologic
abnormalities in individuals with NS and to
better define the impact of the PTPN11 lesion
on the disease course in patients with NS/
MPDandJMML. (Blood.2005;106:2183-2185)
© 2005 by The American Society of Hematology
Introduction
The PTPN11 proto-oncogene encodes Src-homology tyrosine phospha-
tase 2 (SHP-2), a protein tyrosine phosphatase with a role in signal
transduction and hematopoiesis.1,2 Somatic PTPN11 mutations exist in
35% of juvenile myelomonocytic leukemia (JMML) specimens and are
less frequent in other leukemias.3-6 SHP-2 relays signals from activated
growth factor receptors to Ras. PTPN11, KRAS2, NRAS, and NF1
mutations are found in mutually exclusive subsets of patients with
JMML.3,4 These data support the hypothesis that hyperactive Ras
signaling plays a central role in JMML.
Germ-line PTPN11 mutations cause approximately 50% of
cases of Noonan syndrome (NS),7,8 a congenital disorder character-
ized by facial anomalies, short stature, and heart defects.9 Whereas
NS is frequently inherited as an autosomal dominant condition,
almost half of the constitutional PTPN11 mutations found in NS
arise sporadically. Germ-line PTPN11 mutations are also found in
patients with multiple lentigene syndrome (LS), a rare developmen-
tal disorder clinically related to NS.9 Infants with NS are predis-
posed to developing a myeloproliferative disorder (NS/MPD),
which may regress without treatment or follow an aggressive
clinical course similar to JMML.10-14 By contrast, cases of JMML
that arise in patients without NS have a poor prognosis without
hematopoietic stem cell transplantation.15-18 Recent studies show
that children with JMML have improved outcomes when they are
treated aggressively early in the course of disease.18 Therefore,
differentiating JMML from NS/MPD and identifying patients with
NS/MPD who will require aggressive treatment are important
clinical questions. We identify PTPN11 mutations in 77 newly
reported patients with JMML and NS/MPD, and compare the
mutational spectrum in JMML, NS/MPD, and NS/LS to determine
if genotype-phenotype correlations exist that may help guide
diagnosis and clinical management.
Study design
Tissue samples (bone marrow, peripheral blood, and, rarely, buccal swab
and skin fibroblasts) from patients with JMML and NS/MPD were collected
under Institutional Review Board–approved protocols at each institution
and with informed consent. DNA was extracted and analyzed for mutations
in Freiburg, Germany; New York, New York; Rome, Italy; Nagoya, Japan;
and San Francisco, CA. Since the data accumulated thus far have
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demonstrated that PTPN11 mutations in myeloproliferative disorders occur
in exons 3 (90%) or 13 (10%),3,4 these were the only exons screened in
many of the European and American cases as previously described.3,4,8
Mutations in the JMML cases from Nagoya were detected by analyzing
exons 3, 8, and 13 employing standard cloning and sequencing techniques.
Results and discussion
Results of the PTPN11 mutational screening performed on the 77
newly reported patients (JMML 69, NS/MPD 8) are listed in
Table 1. Two mutations, 155C  T (Thr52Ser) and 226-
227GA AT (Glu76Met), had not been previously documented in
JMML or other malignancies.3-6,19,20 Figure 1 shows an updated
compendium of PTPN11 mutations previously documented in
JMML or NS/MPD combined with the current cohort of 77 newly
reported patients. The series includes 107 JMML cases, 19 patients
with NS/MPD, and 243 patients with NS or LS. While other exons
are commonly mutated in the germ line of patients with NS and LS,
only cases with exon 3 and 13 mutations are listed in Figure 1.
All defects with the exception of 2 result in an amino acid
substitution. While there is overlap with respect to the substitutions
seen in patients with NS/MPD and NS (Figure 1; Asp61Gly,
Tyr62Asp, Ala72Gly, Thr73Ile, Ser502Thr, and Gly503Arg) or LS
(Arg498Trp, Gln506Pro), only the Asp61Gly mutation is shared
among patients with JMML, NS/MPD, and NS. Remarkably, 45
(42%) of the mutations found in JMML cases alter codon 76.
Mutations affecting Glu76 are rare in individuals with NS ( 3% of
cases), but are conservative (Glu76Asp) when they occur.
We identified a 214G A (Ala72Thr) mutation in the bone
marrow specimen of a 5-month-old girl with JMML for whom
umbilical cord was collected at birth. Remarkably, the cord blood
contained the same PTPN11 mutation, which was absent in the
child’s buccal cells and parental DNA. Despite the assumption that
JMML arises in utero, this is, to our knowledge, one of the first
demonstrations that a somatically acquired JMML-associated
PTPN11 mutation occurred before birth.
In this newly reported cohort of 77 patients (Table 1), 6
missense changes, including 1 novel mutation affecting exon 13,
1504T G (Ser502Ala), were identified in 8 NS/MPD specimens.
We had buccal swab DNA (n 2) and skin fibroblast DNA (n 1)
available for analysis from 3 patients and confirmed the presence of
the PTPN11 mutation in each case, supporting the germ-line origin
of the lesion. Together with previous data, the Thr73Ile substitution
was identified in 8 out of 19 NS/MPD cases (Figure 1), represent-
ing the most common mutation in patients with NS/MPD. This
mutation is uncommon in NS patients without MPD, and has not
been observed among patients with JMML.
Analysis of DNA from the unaffected parents of 3 children with
NS/MPD with different PTPN11 mutations (Asp61Gly, Ser502Ala,
and Gly506Pro) demonstrated the sporadic origin of each lesion.
Consistent with these results, all previous children with NS/MPD
carrying a mutated PTPN11 gene have been documented to
be sporadic cases.3,14 These findings suggest that NS/MPD is
associated with mutations that might be associated with decreased
fertility or have more severe consequences on fetal survival. This is
consistent with the observation that mutations associated with
NS/MPD have only rarely been identified in patients with familial
NS cases, and that mutants detected in families transmitting NS are
unlikely to be associated with NS/MPD.7,21-25
We identified 1 patient with JMML carrying a somatic 182AG
(Asp61Gly) mutation previously associated with NS.7 The mutation was
found in hematopoietic cells but was absent in skin fibroblasts. The same
mutation was found in 2 patients with NS/MPD. In one of the latter
patients the germ-line nature of this lesion was confirmed by analyzing
buccal cells. To our knowledge, the 182AG (Asp61Gly) mutation is
the only PTPN11 mutation associated with JMML, NS/MPD, and NS.
Figure 1. PTPN11 mutations in JMML, NS/MPD, and
NS/LS. The middle sections of both panels show wild-type
SHP2 amino acid residue at each position. (A) Residues
located within the N-SH2 domain encoded by exon 3. (B)
Residues located within the portion of the catalytic domain
encoded by exon 13. Amino acid substitutions documented in
JMML and NS/MPD (italics), and in NS and LS (italics) are
shown above and below the wild-type SHP2 sequence,
respectively. Del indicates a deletion of this amino acid. Digits
in parentheses indicate the numbers of individuals with JMML,
NS/MPD, or NS carrying a specific mutation. Novel mutations
are identified by asterisks. Whereas virtually all mutations in
JMMLand NS/MPD are located within these confined regions,
mutations associated with NS alone alter other residues of
SHP2 in approximately 50% of the cases.9 Our data, updated
to January 2005, includes 107 cases with JMML, 19 with
NS/MPD, 181 with NS, and 42 with LS.
Table 1. PTPN11 mutations in 77 newly reported children
with JMML or NS/MPD
Cohort, no. cases Nucleotide substitution Amino acid substitution
JMML, N 69
1 155C  G* Thr52Ser
1 178G  C Gly60Arg
9 179G  T Gly60Val
6 181G  T Asp61Tyr
6 182A  T Asp61Val
1 182A  G Asp61Gly
5 214G  A Ala72Thr
4 215C  T Ala72Val
20 226G  A Glu76Lys
6 227A  G Glu76Gly
1 226-227GA  AT* Glu76Met
5 1508G  C Gly503Ala
4 1508G  T Gly503Val
NS/MPD, N 8
2 182A  G Asp61Gly
1 215C  G Ala72Gly
2 218C  T Thr73Ile
1 1492C  T Arg498Trp
1 1504T  G* Ser502Ala
1 1517A  C Gly506Pro
*Novel mutation.
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The finding of Asp61Gly in JMML and NS/MPD is intriguing as this
substitution was used to generate a mouse knock-in model of NS.26
When homozygous, the Asp61Gly mutant is embryonic lethal, whereas
heterozygotes have decreased viability. Of note, while the JMML-like
picture in infants with NS usually develops at or shortly after birth,
Ptpn11Asp61Gly/ mice show signs of a mild myeloproliferative disorder
and splenomegaly by 5 months of age.
Similar to what is observed in NS, the vast majority of
mutations identified in JMML and NS/MPD alter residues located
at the interface between the N-terminal Src homology 2 (N-SH2)
and catalytic (protein tyrosine phosphatase [PTP]) domains.27 They
are predicted to promote SHP-2 gain of function by impairing the
switch between the active and inactive conformation of the protein,
favoring a shift in the equilibrium toward the former. One
exception is the Thr52Ser substitution, which affects the N-SH2
phosphotyrosyl-binding site.27 It has been hypothesized that the
genotype-phenotype relationships observed in patients with so-
matic and germ line mutations of PTPN11 are due to distinct
gain-of-function effects on the protein product SHP-2.3 Consistent
with this view, somatically acquired JMML-associated PTPN11
mutations are predicted to have a strong gain-of-function effect that
might otherwise affect embryonic/fetal development if transmitted
in the germ line, explaining why these mutations are not seen in
NS. In contrast, germ-line mutations identified in NS are predicted
to have weaker hematologic effects. It is also possible that the rare
germ-line PTPN11 lesions observed in NS/MPD can exhibit
intermediate effects. Indeed, in vitro and in vivo experiments on
primary hematopoietic cells and cell lines show that somatic
mutants confer more pronounced effects on cell growth than
common mutants only found in NS,28-30 and exhibit an increased
phosphatase activity basally.3
Our data raise a number of new questions. First, are somatic
PTPN11 mutations sufficient to initiate MPD and, if not, what are
the cooperating molecular lesions? Second, do specific PTPN11
mutations have different consequences depending on whether they
involve the entire hematopoietic compartment or arise as clonal
events? Third, do some patients with NS and PTPN11 mutations
develop transient myeloproliferation, which is unrecognized? Fi-
nally, does the nature of a PTPN11 mutation (germ-line versus
somatic) and the specific amino acid substitution detected provide
information that can be used to guide decisions regarding the need
to initiate aggressive treatment in infants presenting with JMML?
These questions will be answered through ongoing collaborations
between laboratory researchers and clinical investigators who are
evaluating and treating children with these disorders.
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